<DOC>
	<DOCNO>NCT01497964</DOCNO>
	<brief_summary>Primary Objective : - To evaluate anti-tumor activity cabazitaxel assess objective tumor response rate ( ORR ) recommend dose ( RD ) administer single agent every 3 week patient advance gastric adenocarcinoma fail prior chemotherapy regimen Secondary Objectives : - To determine RD cabazitaxel administer single agent every 3 week - To evaluate safety cabazitaxel administer single agent every 3 week - To estimate overall survival ( OS ) progression free survival ( PFS ) - To assess pharmacokinetics ( PK ) profile cabazitaxel part 1</brief_summary>
	<brief_title>Cabazitaxel Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy</brief_title>
	<detailed_description>Patients treat disease progression , unacceptable toxicity , patient 's refusal study treatment . All patient follow study treatment death end study , whichever come first .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically confirm unresectable metastatic gastric adenocarcinoma include adenocarcinoma gastroesophageal junction , fail 2 prior chemotherapy regimen . ( For country standard care establish 2nd line treatment advance gastric cancer , fail 1 2 prior chemotherapy regimen include ) Signed informed consent Exclusion criterion : Patients receive &gt; 2 prior systemic chemotherapy regimen advance gastric cancer . For patient enter part 2 , without least one measurable lesion baseline accord Response Evaluation Criteria Solid Tumors 1.1 criterion Eastern Cooperative Oncology Group performance status &gt; 1 Age &lt; 18 year Inadequate organ bone marrow function Prior surgery , chemotherapy , target agent , investigational agent , anticancer therapy within 4 week prior enrollment study Prior radiation therapy within 6 week prior enrollment ( except palliative radiation local pain control ) Previous treatment cabazitaxel Known brain leptomeningeal involvement cancer Patients know acquired immunodeficiency syndrome ( AIDS ) relate illness know HIV infection require antiretroviral treatment . Patients active varicella zoster infection , know hepatitis B C infection . History severe hypersensitivity reaction â‰¥ grade 3 drug formulate polysorbate 80 docetaxel The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>